Vector Development
Anionic dendrimers convey antisense oligonucleotides to cancer cell targets
Published in Gene Therapy Weekly, December 9th, 2004
According to a study from Wales, "the optimal design of hybridization-competent antisense oligonucleotides (ODNs) coupled with an efficient delivery system appear to be important prerequisites for the successful use of antisense reagents for gene silencing."
"We selected an antisense ODN complementary to an accessible region of the epidermal growth factor receptor (EGFR) mRNA with the aid of an antisense oligonucleotide scanning array. The scanning array comprised 2684 antisense ODN sequences targeting the first 120 nts in the coding region of EGFR mRNA," said M. Hussain and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2004-12-09)
More Articles from Gene Therapy Weekly
- Cancer Vaccines
Interleukin-15 transfection plus CD8+ T cells cause colon cancer rejection - Dermatology
T-oligos trigger anticancer activity in melanoma cells - Gastroenterology
Cytotoxic gene therapy is selective for human pancreatic cancer cells - Urological Oncology
Bladder tumors respond to non-viral tumor necrosis factor-alpha gene transfer - Viral Vectors
Biological and physical titers should be counted in virus-based gene therapy - Adenovirus
Nuclear localization of adenovirus E4orf4 protein correlates with cell death - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
